All Assay Guidance Manual content, except where otherwise noted, is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported license (CC BY-NC-SA 3.0), which permits copying, distribution, transmission, and adaptation of the work, provided the original work is properly cited and not used for commercial purposes. Any altered, transformed, or adapted form of the work may only be distributed under the same or similar license to this one.
Table 21:
Year 1 | |||||
---|---|---|---|---|---|
Decision Point | Cost | Q1 | Q2 | Q3 | Q4 |
#1 Clinical Formulation Development | $250,000 | $250,000 | |||
Prototype development | Variable | ||||
Analytical methods development | Variable | ||||
Prototype stability | Variable | ||||
Prototype selection | Variable | ||||
Clinical supplies release specification | Variable | ||||
(Submit invention disclosure on novel formulation) | Variable | ||||
#2 Development Plan | $300,000 | $550,000 |
Copyright Notice
- Guidelines, editors, pharma and the biological paradigm shift.[Mens Sana Monogr. 2007]Guidelines, editors, pharma and the biological paradigm shift.Singh AR, Singh SA. Mens Sana Monogr. 2007 Jan; 5(1):27-30.
- Review [Development of antituberculous drugs: current status and future prospects].[Kekkaku. 2006]Review [Development of antituberculous drugs: current status and future prospects].Tomioka H, Namba K. Kekkaku. 2006 Dec; 81(12):753-74.
- Erratum: Eyestalk Ablation to Increase Ovarian Maturation in Mud Crabs.[J Vis Exp. 2023]Erratum: Eyestalk Ablation to Increase Ovarian Maturation in Mud Crabs.. J Vis Exp. 2023 May 26; (195). Epub 2023 May 26.
- "New drug" designations for new therapeutic entities: new active substance, new chemical entity, new biological entity, new molecular entity.[J Med Chem. 2014]"New drug" designations for new therapeutic entities: new active substance, new chemical entity, new biological entity, new molecular entity.Branch SK, Agranat I. J Med Chem. 2014 Nov 13; 57(21):8729-65. Epub 2014 Sep 4.
- Review Drug repurposing in rare diseases: Myths and reality.[Therapie. 2020]Review Drug repurposing in rare diseases: Myths and reality.Fetro C, Scherman D. Therapie. 2020 Apr; 75(2):157-160. Epub 2020 Feb 13.
- Table 21: [Clinical Formulation Development]. - Assay Guidance ManualTable 21: [Clinical Formulation Development]. - Assay Guidance Manual
- Taxonomy Links for Nucleotide (Select 1783496759) (1)Taxonomy
- NRCAM neuronal cell adhesion molecule [Homo sapiens]NRCAM neuronal cell adhesion molecule [Homo sapiens]Gene ID:4897Gene
- Gene Links for Protein (Select 2462614535) (1)Gene
- Mus musculus nucleoporin 188 (Nup188), transcript variant 3, mRNAMus musculus nucleoporin 188 (Nup188), transcript variant 3, mRNAgi|2280436459|ref|NM_001410239.1|Nucleotide
Your browsing activity is empty.
Activity recording is turned off.
See more...